Covidien , a leading global supplier of healthcare products, today announced that Stacy Enxing Seng has been appointed President of the Company’s Vascular Therapies Global Business Unit. She will report directly to Peter L. Wehrly, Senior Vice President and Group President, Respiratory & Monitoring Solutions and Vascular Therapies.
Enxing Seng, 47, will be responsible for managing a global organization of 4,000 employees with $1.4 billion in revenue. She joined Covidien in July 2010 through the ev3 acquisition, where she was a founding member and executive officer responsible for leading ev3’s Peripheral Vascular Division from inception to a $350 million business.
“Stacy has a proven track record in leading and growing businesses,” said Wehrly. “Her experience at ev3, focus on the customer and the employee, combined with her strong knowledge of the vascular market makes her the ideal candidate to lead our Vascular business.”
Prior to joining ev3, Stacy held various positions of increasing responsibility for Boston Scientific, SCIMED Life Systems Inc., Baxter Healthcare and American Hospital Supply. She received an MBA from Harvard University and a bachelor’s degree from Michigan State University.
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2011 revenue of $11.6 billion, Covidien has 41,000 employees worldwide in more than 65 countries, and its products are sold in over 140 countries.